Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10221682 | 0.82 | ALDH1A1 (0.50) | ACHEALDH1A1NPC1RAB9AKDM4E | |
| SCHEMBL28192184 | 0.81 | HTR2B (0.44) | ACHEMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL14656020 | 0.80 | ACHE (0.64) | MAOAACHEMAPTMEN1KMT2A | |
| SCHEMBL4540623 | 0.79 | MAOA (0.51) | MAOAACHEMAPTMEN1KMT2A | |
| SCHEMBL162485 | 0.78 | MAOA (0.50) | MAOAACHEMAPTMEN1KMT2A | |
| SCHEMBL496467 | 0.78 | MAOA (0.50) | MAOAACHEMAPTMEN1KMT2A | |
| SCHEMBL595766 | 0.78 | MAOA (0.50) | MAOAACHEMAPTMEN1KMT2A | |
| SCHEMBL20067892 | 0.78 | MAOA (0.47) | MAOAACHEMAPTMEN1KMT2A | |
| SCHEMBL9255563 | 0.78 | HPGDS (0.38) | MAPTKMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL230453 | 0.77 | MAPT (0.65) | MAOAACHEMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220396586-A1 | THIAZOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) | 2022-12-15 | — | — | US | disclosed |
| US-20220396586-A1 | THIAZOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) | 2022-12-15 | — | — | US | disclosed |
| EP-4034106-A1 | THIAZOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | The Global Alliance for TB Drug Development, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| CN-114746089-A | Thiazolecarboxamide compounds and their use for the treatment of mycobacterial infections | 结核病药物开发全球联盟公司 | 2022-07-12 | — | — | CN | disclosed |
| WO-2021062318-A1 | THIAZOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| WO-2021062318-A1 | THIAZOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| CN-107406427-A | Alkynyl alcohols and methods of use thereof | 豪夫迈·罗氏有限公司 | 2017-11-28 | — | — | CN | disclosed |
| US-20150080569-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-8809266-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20130274439-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-17 | — | — | US | disclosed |
| US-8420597-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-20130053577-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| US-8178491-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090257978-A1 | Antiviral coumpounds | GILEAD SCIENCES, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| EP-0199324-B1 | NEW 2,5-DIARYL TETRYHYDROFURANS AND ANALOGS THEREOF AS PAF ANTAGONISTS | MERCK & CO. INC. (US) | 1991-10-02 | — | — | EP | disclosed |
| EP-0322033-A2 | New 2,5-diaryl tetrahydrofurans and analogs thereof as paf antagonists | MERCK & CO. INC. (US) | 1989-06-28 | — | — | EP | disclosed |
| EP-0199324-A2 | New 2,5-diaryl tetryhydrofurans and analogs thereof as paf antagonists | MERCK & CO. INC. (US) | 1986-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274439-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | MAOA 3729/4885ACHE 4093/4885MAPT 2923/4885 |
| US-20090257978-A1 | Antiviral coumpounds | MAVS, ZC3HAV1, EIF2AK2 | MAOA 3910/4885ACHE 3480/4885MAPT 3331/4885 |
| US-20130053577-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | MAOA 3729/4885ACHE 4093/4885MAPT 2923/4885 |
| US-20220396586-A1 | THIAZOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GOT2, ABAT, SDHA | MAOA 934/4885ACHE 2734/4885MAPT 1641/4885 |
| US-20150080569-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | MAOA 3729/4885ACHE 4093/4885MAPT 2923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.